Patient Derived Acute myeloid leukemia (AML) models

We provide access to several different AML PDX models currently available in the highly immunodeficient NSG™-SGM3 mouse strain, which engrafts leukemia cells more effectively than other strains (Sanchez, et al. 2009; Diamanti, et al. 2011). NSG-SGM3  mice engrafted with AML PDX samples are available for efficacy testing at JAX® In Vivo Services or for distribution to your laboratory.

In line with our mission to support biomedical research and drug discovery, we are now validating engrafted NSG™ mice with additional patient-derived Acute Myeloid Leukemia to make them available for you soon.

Model Name Diagnosis Karyotype FLT3 IDT IDH1 mutation In stock
J000096994 AML 46 XY[20] Positive Negative Yes

Advantages of JAX AML Models

  • Confirmed robust engraftment of the primary leukapheresed AML samples in NSG™-SGM3 mice
  • Approximately 500 mice can be engrafted for AML model J000096994 to support longitudinal studies
  • Client sponsored efficacy studies can be executed by the JAX® In Vivo Pharmacology Services group.
  • Engrafted mice can be delivered to your facility for downstream studies.

Table 1. J000096994 is an aggressive AML, positive for FLT3-ITD


* The complete genomic report listing SNVs, insertions and deletions, plus the complete set of clinical evidence for drug sensitivity efficacy are available upon request.

Robust AML Growth Kinetic Post-Engraftment


Figure 1. Robust engraftment of samples derived from patients with AML in NSG-SGM3 mice. Peripheral blood of mice 10-16 weeks post injection show engraftment levels > 5% for PDX model J000096994 (bottom panel), respectively. The progression of AML was measured by flow cytometry using monoclonal antibodies targeting the human surface marker CD33.

Models Display Positive Responses to Standard-of-Care Treatment with ARA-C


Figure 2. NSGTM-SGM3 mice are a robust preclinical model for AML. A) JAX AML model J000096994. Note that by day 21, AML comes back after treatment, recapitulating what is often observed in blood and bone marrow from patients. The upper panels display the respective growth rates of AML samples detected in peripheral blood in the presence or absence of arabinofuranosyl cytidine (Ara-C). Mice were engrafted with patient-derived AML cells and were either treated with Ara-C (30 mg/kg) for 5 consecutive days and engraftment levels and response to treatment were compared to untreated controls (untreated). Average engraftment levels at terminus are shown for blood, bone marrow, and spleen samples. 

Table 3. Actionable mutations known to be sensitive to drugs indicated for AML2


2 The Genomics analysis was performed using the JAX-Clinical Knowledgebase (CKB) - a powerful tool for interpreting complex genomic profiles, and represents a valuable resource for clinicians and translational and clinical researchers.

Contact Us